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IMPORTANCE Although the usefulness of polygenic risk scores as a measure of genetic liability
for major depression (MD) has been established, their association with depression in the
general population remains relatively unexplored.
OBJECTIVE To evaluate whether polygenic risk scores for MD, bipolar disorder (BD), and
schizophrenia (SZ) are associated with depression in the general population and explore
whether these polygenic liabilities are associated with heterogeneity in terms of age at onset
and severity at the initial depression diagnosis.
DESIGN, SETTING, AND PARTICIPANTS Participants were drawn from the Danish iPSYCH2012
case-cohort study, a representative sample drawn from the population of Denmark born
betweenMay 1, 1981, and December 31, 2005. The hazard of depression was estimated using
Cox regressions modified to accommodate the case-cohort design. Case-only analyses were
conducted using linear andmultinomial regressions. The data analysis was conducted from
February 2017 to June 2018.
EXPOSURES Polygenic risk scores for MD, BD, and SZ trained using themost recent
genome-wide association study results from the Psychiatric Genomics Consortium.
MAIN OUTCOMES ANDMEASURES Themain outcomewas first depressive episode
(International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision [ICD-10] code F32) treated in hospital-based psychiatric care. Severity at the initial
diagnosis was measured using the ICD-10 code severity specifications (mild, moderate, severe
without psychosis, and severe with psychosis) and treatment setting (inpatient, outpatient,
and emergency).
RESULTS Of 34 573 participants aged 10 to 31 years at censoring, 68% of those with
depression were female compared with 48.9% of participants without depression. Each SD
increase in polygenic liability for MD, BD, and SZ was associated with 30% (hazard ratio [HR],
1.30; 95% CI, 1.27-1.33), 5% (HR, 1.05; 95% CI, 1.02-1.07), and 12% (HR, 1.12; 95% CI, 1.09-1.15)
increases in the hazard of depression, respectively. Among cases, a higher polygenic liability
for BDwas associated with earlier depression onset (β = −.07; SE = .02; P = .002).
CONCLUSIONS AND RELEVANCE Polygenic liability for MD is associated with first depression in
the general population, which supports the idea that these scores tap into an underlying
liability for developing the disorder. The fact that polygenic risk for BD and polygenic risk for
SZ also were associated with depression is consistent with prior evidence that these disorders
share some common genetic overlap. Variations in polygenic liability may contribute slightly
to heterogeneity in clinical presentation, but these associations appear minimal.
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G enesplay amoderate role in the etiologyofdepression,withtwin-basedheritabilityestimatesrangingfrom30%to 40%1 and single-nucleotide polymorphism (SNP)–
based heritability estimates ranging from 9% to 29%.2-4 Large
empirical studiesof thegenetic architectureofdepression indi-
cate that it ispolygenic,meaningthat thecontributionofgenetic
factors is attributable to small effectsofhundredsor thousands
of genetic variants spread across the genome.3,5
Todate,multiple studieshaveshownsmallbut statistically
significant associations betweenpolygenic risk scores (PRSs) a
weighted sum of the number of variants associated with the
disorderinadifferentdataset,anddepression.6-9However,these
studies focused on prevalent depression, which is more likely
than incidentdepressiontoberecurrentorchronic.10,11Because
thegenome-wideassociationstudy (GWAS)dataunderpinning
thePRSsare largelybasedonprevalentcases, thiscouldsuggest
that part of the genetic architecture discovered in GWAS stud-
ies is linked to chronicity or recurrence rather than the risk of
developingthedisorder.Therefore,while theusefulnessofPRSs
as ameasure of genetic liability for depression has been estab-
lished, their associationwithdepression in thegeneralpopula-
tion remains, to our knowledge, relatively unexplored.
In addition to heterogeneity in chronicity and recurrence,
depression isalsocharacterizedbysubstantialvariation inchar-
acteristics, such as age at onset (AAO) and symptom severity.
Researchsuggests that thisvariationmaybepartiallyduetodif-
ferences ingenetic liability.Family studiesdemonstrate that in-
dividuals with a parental history of major depression (MD) are
at increased risk for onset of depression at earlier ages,12-15 and
recent results fromthePsychiatricGenomicsConsortium(PGC)
showedthat thepolygenic risk fordepressionhadastrongeras-
sociation with early-onset vs late-onset depression.4 Research
alsosuggests that individualswithsevereMDmayhaveahigher
genetic burden than individuals with milder symptoms. A re-
cent GWAS in Han Chinesewomen found an increased genetic
signal among individuals with melancholia,16 and the PGC re-
portedhigherPRSsamongseverevsmoderatedepressioncases.4
Our primary aim in this study was to evaluate the extent
towhich polygenic liability is associatedwith risk for first de-
pressiveepisode in thegeneralpopulation.Asasecondaryaim,
weexaminedwhetherpolygenic liability is associatedwith se-
verity andAAOat firstdepressiondiagnosis.Becauseprior evi-
dence suggests apossible sharedgenetic etiologybetweende-
pressionandotherpsychiatricdisorders,2,4,17wealsoexamined
the extent towhich PRSs for bipolar disorder (BD) and schizo-
phrenia (SZ) are associated with the risk for developing de-
pression in the general population. To accomplish these aims,
we used data from the iPSYCH2012 sample, a unique data set
that linksgenetic informationwith longitudinalphenotypedata
from Danish national registers.
Methods
Study Design
For a detailed description of the iPSYCH2012 sample, see
Pedersen et al.18 Briefly, the iPSYCH2012 sample has a case-
cohort design19 that consists of 2 parts: a random sample (ie,
subcohort) of individuals drawn from a specified base popu-
lation (ie, full cohort) and all additional cases from the full co-
hort thatwerenot selected as part of the subcohort. Like a tra-
ditional cohort study, a case-cohort study canobtain accurate
estimatesofhazardsandrisksusingatraditional survivalanaly-
sis, provided the analyses are modified to address issues as-
sociated with point and variance estimations that are caused
byoversampling cases.19-22 For amoredetaileddescription of
the case-cohort design see the eMethods in the Supplement.
In the iPSYCH2012 sample, the subcohort consists of a ran-
dom sample of 30000 individuals drawn from the full cohort
of all singletons born in Denmark between May 1, 1981, and
December 31, 2005, who were alive and living in Denmark on
their firstbirthdayandhadknownmothers(N = 1472762).18The
full cohort was identified using information from the Danish
Civil Registration system.23 The iPSYCH2012 study includes all
individuals fromthe full cohortwho receivedadiagnosis ofde-
pression inapsychiatrichospital inDenmarkbetween1991and
2012 at 10 years or older. Information on psychiatric diagnoses
was obtained from the Danish Central Psychiatric Research
Register (DCPRR).24 Diagnoses are based on the ICD-10
Classification of Mental and Behavioral Disorders: Diagnostic
Criteria for Research (ICD-10).25
Sample Selection
We began by selecting all members of the subcohort and all
cases outside the subcohort whose first depression diagnosis
in the DCPRR was F32 (depressive episode). We focused ex-
clusively on individuals with Danish-born parents to reduce
heterogeneity in genetic ancestry. The samplewas further re-
stricted to individualswhoweresuccessfullygenotypedaspart
of the iPSYCH2012 sample, passed quality control (QC) mea-
sures, and were alive, living in Denmark, and at least age 10
years by the end of follow-up (December 31, 2012). Seventy-
six individualswere removedfromthesubcohortbecause their
firstdepressiondiagnosis in the registerwasF33 (recurrentde-
pressive disorder) and we were thus unable to identify their
first depressive episode. The final sample included 34573 in-
dividuals. Of the 14 799 members with a depression diagno-
sis, 308 (2.1%) weremembers of the subcohort and 14491 in-
dividuals (97.9%)were cases outside the subcohort (eFigure 1
in the Supplement). This study was approved by the Danish
Key Points
Question Are polygenic liabilities for major depression, bipolar
disorder, and schizophrenia associated with depression in the
general population?
Findings In this case-cohort study of 34 573 individuals, each 1 SD
increase in the polygenic risk for major depression was associated
with a 30% increase in the hazard for a depression diagnosis in
hospital-based psychiatric care. Polygenic liabilities for
schizophrenia and bipolar disorder were also associated with an
increased hazard of depression but to a lesser extent.
Meaning Polygenic risk scores trained in samples of prevalent
major depression cases are associated with first depression in the
general population.
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Data Protection Agency. By Danish law, register-based stud-
ies do not require informed consent.
Genotyping
For a more detailed description of genotyping and QC in the
iPSYCH2012 cohort, see Pedersen et al.18 Briefly, DNA was
collected fromblood spots that were drawn as part of routine
clinical testing at birth and stored at the Danish Neonatal
Screening Biobank.26 Blood spots were located for 80 422
of 86 189 members (93.3%) of the original iPSYCH2012
sample. Genotyping was performed at the Broad Institute of
Harvard University and Massachusetts Institute of Technol-
ogy (Cambridge, MA) using the Infinium PsychChip array,
version 1.0 (Illumina) according to the manufacturer’s
protocols.27 Quality control and imputation (using 1000
genomes as the reference panel) were conducted using the
Ricopili pipeline. As the iPSYCH2012 sample is population
based, individuals from the same nuclear family unit were
neither purposely sampled nor purposely removed.
Measures
TheAAOwas operationalized as the individual’s age in years at
firstF32diagnosis intheDCPRR.Informationonseveritywasob-
tainedfromICD-10diagnosticcodes(mild,F32.0;moderate,F32.1;
severewithout psychotic features, F32.2; and severewith psy-
choticfeatures,F32.3).Wealsoexamineddifferencesintreatment
settings (inpatient, emergency, andoutpatient) as cases treated
in inpatient or emergency settings are likely more severe than
cases treated in an outpatient setting.
Polygenic risk scores were calculated using a standard
approach28 in which a linkage disequilibrium–pruned discov-
erydata set is used to identify autosomal SNPs associatedwith
the outcome at varying P value thresholds, and then a score is
calculated for individuals in a target data set that corresponds
to theweighted sumof eachparticipant’s allelic burden at that
threshold.PolygenicriskscoresforMDandSZwerecreatedusing
theRicopili processwith themost recentlypublishedGWASre-
sults fromthePGC(not including iPSYCH2012)asdiscoverydata
sets.4,29 The discovery data set for BD was composed of leave
one out summary statistics provided in advance of the latest
GWASpublicationfromtheBipolarWorkingGroupofthePGC.30
Single-nucleotidepolymorphisms fromthediscoverydata sets
were filtered at an INFO score ofmore than0.9 and aminor al-
lele frequencyofmore than .05, andthebroadmajorhistocom-
patibility complex region (chr6: 25-35 MB) was removed. Ad-
ditionally SNPs were only included in the scores if they were
reliably genotyped or imputed across all 23 waves of the
iPSYCH2012 sample, at an INFO score of more than 0.6 and a
minor allele frequency ofmore than .01. Ten PRSswere calcu-
lated foreachdisorder (30total) at the followingPvalue thresh-
olds: P < .00000005, .000001, .0001, .001, .01, .05, .10, .20,
.50,and>.99(seeeTable1 intheSupplementforSNPnumbers).31
Polygenic risk scores were standardized using the means and
SDs from the distributions in subcohortmemberswithDanish
ancestry (eFigure in the Supplement). As the iPSYCH2012 sub-
cohort is a simple random sample drawn from the base popu-
lation, the distribution of PRSs in the subcohort approximates
the distribution in the Danish-born population.
Statistical Analysis
Thehazard of depressionwas estimatedusingCox regressions
with days since the participant’s tenth birthday as the time-
scale. Individuals entered the analysis on their tenth birthday
andwerecensoredon thedateof their firstF32diagnosis in the
DCPRR, death, emigration, or December 31, 2012, whichever
came first. Theoldestparticipantswereage31yearswhen they
received theirdiagnosisorwerecensored.Weusedrobust stan-
dard errors and Barlowweighting to account for oversampling
of cases.22,32Allmodelswereadjusted for sexand the top4an-
cestralprincipalcomponents(PCs).Additionally,allmodelswere
stratifiedbybirthyear (1981-2002) to control for secular trends
in diagnostic practices and because fewer bloodspots were
retrievable among individuals born during earlier years.
Toexaminewhetherpolygenic liabilityhasa strongerasso-
ciation with early-onset depression, we conducted separate
Cox regressions in each analysis with only depression with
onset inaspecificagerangeconsideredasanoutcome.Thus,we
estimatedseparately theassociationofPRSswithhazardofde-
pressionwithdiagnosisatages 10 to 15, 16 to20,21 to25,and26
to 31 years, respectively. Likewise,we conducted separate Cox
regressions thatconsideredrespectivelymild,moderate, severe
without psychotic features, severewithpsychotic features, in-
patient, emergencyandoutpatient treatment settingat firstde-
pressionasoutcomes ineachof theanalyses.Wealsoexamined
theassociationsbetweenPRSs,AAO,andseverity amongcases
only.AssociationswithAAOindayswereestimatedusing linear
regressions.Associationswithseveritymeasureswereestimated
Table 1. Sample Characteristics
Characteristic
Case Status, No. (%)
Participants
Without Depression
Participants
With Depression
Sex
Male 10 115 (51.2) 4743 (32.1)
Female 9659 (48.9) 10 056 (68.0)
Age at depression diagnosis, y
Noncase 19 774 (100.0) NA
10-15 NA 2965 (20.0)
16-20 NA 6653 (45.0)
21-25 NA 3981 (26.9)
26-31 NA 1200 (8.1)
ICD-10 severity specifier
Noncase 19 774 (100.0) NA
Mild NA 2573 (17.4)
Moderate NA 6635 (44.8)
Severe without psychotic
symptoms
NA 1386 (9.4)
Severe with psychotic
symptoms
NA 481 (3.3)
Severity unspecified NA 3724 (25.2)
Treatment setting
Noncase 19 774 (100.0) NA
Outpatient NA 8880 (60.0)
Inpatient NA 2269 (15.3)
Emergency NA 3650 (24.7)
Total sample 19 774 (100.0) 14 799 (100.0)
Abbreviations: ICD-10, International Statistical Classification of Diseases and
Related Health Problems, Tenth Revision; NA, not applicable.
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usingmultinomial logistic regressions.All case-onlyregressions
were adjusted for the first 4 PCs, sex, and birth year. Statistical
significance was assessed at the Bonferroni-corrected α-level
P < .017. Analyses were conducted in SAS, version 9.4 (SAS
Institute; eAppendix in the Supplement).
Results
Sample Characteristics
Table 1 shows sample characteristics.Of theparticipantswith-
out depression, 9659 (48.9%) were female, which was ex-
pected given that the subcohort is a representative sample of
the Danish population. Of the participants with MD, 10056
(68.0%)were female, whichwas also expected given that the
typical female tomale ratio of depression in the population is
2:1.33 TheAAO ranged from 10 to 31 years,with amean (SD) of
19.1 (4.1) years. Seventeenpercent of the caseswere classified
as mild (n = 2573), 45% as moderate (n = 6635), 9% as severe
(n = 1386), 3% as psychotic (n = 481), and 25% had no ICD-10
severity specification (n = 3724). Most (60%; n = 8880) were
treated in an outpatient setting.
Polygenic Liability and Hazard of Depression
For all 3 PRSs (PRS-MD, PRS-BD, and PRS-SZ), the strength of
the association increased as the stringency of the P value
threshold decreased up to P<.05 (eTable 2 and eFigures 2-7
in the Supplement). For this reason, and to maintain consis-
tency with prior research, we present results from the P<.05
thresholds throughout this article.
Each SD increase in PRS-MD was associated with a 30%
increase in the hazard of depression (95% CI, 1.27-1.33;
P < .0001). Compared with an individual with average poly-
genic liability, an individual who is 1 SD more than the popu-
lation average had a 30% increased risk of receiving a
depression diagnosis before age 31 years. The corresponding
values for PRS-BD and PRS-SZ were 5% (95% CI, 1.02-1.07;
P < .0001) and 12% (95% CI, 1.09-1.15; P < .0001), respec-
tively (eTable 2 in the Supplement). Figure 1 shows the asso-
ciations between PRS deciles and the hazard of depression,
with the bottom decile (ie, the lowest 10% of the PRS distri-
bution) as the reference category. Compared with individu-
als in the bottom decile, individuals in the top decile of
PRS-MD had a hazard ratio of 2.55 (95% CI, 2.28-2.85;
P < .0001). The corresponding values were 1.22 (95% CI,
1.10-1.36; P < .0001) for PRS-BD and 1.49 (95% CI, 1.34-1.66;
P < .0001) for PRS-SZ (eTable 3 in the Supplement).
AAO
As shown inFigure 2 andTable 2, thehazardofdepressionper
SD increase in PRS-MD was slightly higher for first diagnosis
between age 16 to 20 years (1.31; 95% CI, 1.27-1.35) and age 21
to 25 years (1.32; 95% CI, 1.27-1.38) compared with age 10 to
15years (1.27; 95%CI, 1.22-1.33) or age26 to31 years (1.24; 95%
CI, 1.16-1.32). The hazard ratio of PRS-BD was highest for di-
agnosis between ages 10 to 15 years (1.08; 95% CI, 1.04-1.12)
and decreased linearly with age. The hazard ratio between
PRS-SZ and was highest for diagnoses between age 10 to 15
years (1.17; 95% CI, 1.12-1.22) and lowest for diagnoses be-
tween age 21 to 25 years (1.08; 95% CI, 1.04-1.13). Case-only
analyses showed small associations betweenhigher PRSs and
earlier AAO across all scores, but only the association for
PRS-BD survived correction for multiple testing (Table 3).
Severity
Thehazard ratios for PRS-MD, PRS-BD, andPRS-SZwerehigh-
est for psychotic depression (Figure 2, Table 2). The differ-
encesbyseverityweremostpronounced forPRS-SZ (1.20;95%
CI, 1.09-1.32) and least pronounced for PRS-MD (1.33; 95%CI,
1.23-1.45). In the case-only analyses, none of the associations
were statistically significant; however, the association be-
tween higher PRS-SZ and an increased odds of psychotic de-
pression was suggestive (odds ratio, 1.10; 95% CI, 1.00-1.21;
P = .06) (Table 3).
The hazard ratios for PRS-MD, PRS-BD, and PRS-SZ were
higher for treatment in inpatientandemergencysettings;how-
ever, these differences were small (Figure 2). Polygenic risk
scores for MD were marginally associated with an increased
Figure 1. Polygenic Liability forMajor Depressive Disorder (MD), Bipolar Disorder (BD), and Schizophrenia (SZ) and Hazard of Depression
in the iPSYCH2012 Cohort
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A-C, The hazard of depression for each decile of polygenic liability compared with the bottom decile (ie, the bottom 10% of the polygenic liability in the Danish
population). The bars represent 95% confidence intervals.
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odds of emergency treatment in the case-only analyses (odds
ratio, 1.05; 95% CI, 1.01-1.09; P = .02) (Table 3).
Discussion
In this study,we found that PRSs trained using aggregated re-
sults from selected samples of prevalent, often recurrent de-
pressioncases contributed to the risk for firstdepression in the
Danish general population. For each SD increase in polygenic
liability, the hazard of depression increased by 30%. Com-
pared with individuals in the bottom 10% of the polygenic
liability distribution, the hazard of depressionwas 2.55 times
higher among individuals in the top 10%. These results sug-
gest that estimatesof genetic liability ascertainedusingpreva-
lent samples are tapping in to an underlying genetic predis-
position for developing depression, not just a predisposition
to maintain the disorder once it has been established. Poly-
genic liability for BD and SZ were associated with depression
to a lesser extent than PRS-MD, which supports the well-
Figure 2. Polygenic Liability forMajor Depressive Disorder (MD), Bipolar Disorder (BD), and Schizophrenia (SZ) and Hazard of Depression
by Age and Severity
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A-C, Hazard ratios (HRs) per SD increase in polygenic liabilities for MD, BD, and
SZ for a depression diagnosis within different age ranges. D-F, Hazard ratios per
SD increase in polygenic liabilities for MD, BD, and SZ for a depression diagnosis
with different International Statistical Classification of Diseases and Related
Health Problems, Tenth Revision (ICD-10) severity specifications. G-I, Hazard
ratios per SD increase in polygenic liabilities for MD, BD, and SZ for a depression
diagnosis within different treatment settings. The bars represent 95%
confidence intervals. PRS indicates polygenic risk scores.
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documented finding that these disorders share some com-
mon genetic etiology.
Theassociationofpolygenic liabilitywithAAOinthis study
was much smaller than prior findings from family studies
would suggest. This could reflect that PRSs and family back-
ground are not entirely overlappingmeasures of genetic risk.
Previous research suggests that some of the effect of family
historyof schizophrenia ismediatedbypolygenic risk.34 If the
sameholds true for depression, the larger effects identified in
family studies may be attributable to the portion of the fam-
ily history effect not captured by a PRS, or possibly to an in-
creased vigilance for psychiatric disorders among multiplex
families. The oldestmembers of the iPSYCH2012 cohortwere
only age 31 years at the end of follow-up, which is around the
median age of onset for depression.35 As a result, the entire
samplecouldbeconsideredearly-onset. Itmaybethat themore
pronounceddifferencesexist in theeffectsofPRS-MDwith the
risk for depression at different points across the lifespan, but
that thesedifferencesare lessapparentwhencomparinggroups
of younger individuals.
We found little association between polygenic liability
and greater severity at the initial depression diagnosis,
which is inconsistent with recent findings from the PGC.4 In
general, past studies with positive findings in this area have
focused on severity measures that are associated with the ill-
ness course, such as the number of depressive episodes and
the chronicity of depressive symptoms.36-38 It could be that
polygenic liability has less of an effect on characteristics of
the first depressive episode than it does on the characteris-
tics of course.
Table 3. Case-Only Analyses of the Associations of PRS-MD, PRS-BD, and PRS-SZWith Age at Onset and Severity at First Depression Diagnosis
Characteristic
MD BD SZ
β (SE) OR (95% CI) P Value β (SE) OR (95% CI) P Value β (SE) OR (95% CI) P Value
Age at depression
diagnosis
−0.05 (0.02) NA .04 −0.07 (0.02) NA .002 −0.05 (0.02) NA .04
ICD-10 severity
specifier
Mild Reference Category
Moderate −0.00 (0.02) 1.00 (0.95-1.05) .99 −0.03 (0.02) 0.97 (0.93-1.02) .24 0.04 (0.02) 1.04 (0.99-1.09) .08
Severe −0.05 (0.03) 0.95 (0.89-1.01) .13 0.02 (0.03) 1.02 (0.95-1.08) .62 0.02 (0.03) 1.02 (0.95-1.09) .58
Psychotic 0.02 (0.05) 1.02 (0.92-1.12) .71 0.06 (0.05) 1.06 (0.97-1.17) .21 0.09 (0.05) 1.10 (1.00-1.21) .06
Unspecified −0.01 (0.03) 0.99 (0.94-1.04) .77 −0.02 (0.03) 0.98 (0.93-1.03) .48 0.02 (0.03) 1.02 (0.97-1.07) .51
Treatment setting
Outpatient Reference Category
Emergency 0.05 (0.02) 1.05 (1.01-1.09) .02 0.03 (0.02) 1.03 (0.99-1.07) .18 0.03 (0.02) 1.03 (0.99-1.07) .13
Inpatient 0.04 (0.02) 1.04 (0.99-1.09) .13 0.02 (0.02) 1.02 (0.98-1.07) .37 0.02 (0.02) 1.02 (0.97-1.07) .46
Abbreviations: BD, bipolar disorder; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; MD, major depression;
NA, not applicable; OR, odds ratio; PRS, polygenic risk score; SZ, schizophrenia.
Table 2. Associations Between PRS-MD, PRS-BD, and PRS-SZ and Hazard of DepressionWithin Different Age at Onset and Severity Subgroups
Characteristic
MD BD SZ
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age at depression diagnosis, y
10-15 1.27 (1.22-1.33) <.0001 1.08 (1.04-1.12) .0002 1.17 (1.12-1.22) <.0001
16-20 1.31 (1.27-1.35) <.0001 1.04 (1.01-1.07) .008 1.12 (1.09-1.16) <.0001
21-25 1.32 (1.27-1.38) <.0001 1.04 (1.00-1.08) .05 1.08 (1.04-1.13) 0.0001
26-31 1.24 (1.16-1.32) <.0001 1.02 (0.95-1.10) .55 1.12 (1.04-1.19) 0.0018
ICD-10 severity specifier
Mild 1.31 (1.26-1.37) <.0001 1.06 (1.02-1.11) .005 1.09 (1.04-1.14) 0.0002
Moderate 1.31 (1.27-1.35) <.0001 1.03 (1.00-1.06) .04 1.13 (1.10-1.17) <.0001
Severe 1.24 (1.18-1.32) <.0001 1.08 (1.02-1.14) .009 1.11 (1.05-1.18) 0.0004
Psychotic 1.33 (1.23-1.45) <.0001 1.13 (1.03-1.24) .01 1.20 (1.09-1.32) <.0001
Unspecified 1.30 (1.25-1.35) <.0001 1.04 (1.01-1.08) .02 1.11 (1.07-1.15) <.0001
Treatment setting
Emergency 1.34 (1.29-1.39) <.0001 1.07 (1.03-1.11) .001 1.14 (1.10-1.18) <.0001
Inpatient 1.33 (1.27-1.39) <.0001 1.06 (1.01-1.11) .01 1.13 (1.08-1.18) <.0001
Outpatient 1.28 (1.24-1.32) <.0001 1.04 (1.01-1.07) .008 1.11 (1.08-1.14) <.0001
Abbreviations: BD, bipolar disorder; HR, hazard ratio; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision;
MD, major depression; PRS, polygenic risk score; SZ, schizophrenia.
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It has been suggested previously that stratifying on the
phenotypemaybeaviablemethodto increasestatisticalpower
for identifying genetic variants that are associated with
depression.39 This method has been used with some success
by the CONVERGE consortium, which identified a locus that
was significantly associated with depression in Han Chinese
womenbyselecting forhighly severe, recurrent femalecases.16
Polygenic risk was also found to be differentially associated
with subtypes in autism,31 BD, andSZ.30However, for depres-
sion, greater success in gene discovery was achieved by in-
creasing the sample size at the expense of a carefully defined
phenotype.4,40 In this vein, the results of this study indicate
that the usefulness of further stratification on the phenotype
for gene discovery in depression might be more limited than
wemay have wished.
We found someevidence of genetic heterogeneity among
depressioncases in termsofpolygenic liabilities forBDandSZ:
there was a suggestive (although not significant) association
between PRS-SZ and depression with psychotic symptoms,
which makes intuitive sense. The PRS for BD was signifi-
cantly associated with earlier age at MD onset in the case-
only analyses, and the case-cohort analyses in separate age
groups suggest that PRS-BD and PRS-SZ may be particularly
elevated among individuals who receive a diagnosis withMD
between the ages of 10 to 15 years. These results are consis-
tentwithpast studies41,42 andcould suggest that aperson’sde-
gree of genetic liability for BD or SZ may place them at an in-
creased risk fordifferent clinicalmanifestationsofdepression.
However, psychiatric diagnoses are often unstable over time,
and both early AAO and greater severity/psychotic symp-
toms are robust risk factors for converting to BD or SZ.43-45
It is therefore possible that these results reflect that many
individuals with BD and SZ receive a depression diagnosis
during the early stages of their illness.
Strengths and Limitations
The iPSYCH2012 samplehasmany strengths, including a large
sample size, population-based sampling, and a uniform case
definition. The fact that cases were identified through clini-
cal records rather than selected specifically for research in-
creases the relevance for clinical practice. In addition, the
ancestral homogeneity of the Danish population reduces the
likelihood of confounding by population stratification.
However, it should be noted that although cases in the
iPSYCH2012 sample are representative of individualswho re-
ceived treatment for depression in psychiatric hospitals, they
do not include people with depression who are untreated or
only treatedby general practitioners.46,47 Toput this into per-
spective, currently unpublished results show thatmost (85%)
individuals who are medically treated for depression in Den-
mark are treated first by their primary care doctors, although
this proportion was lower in younger age groups (unpub-
lisheddata, 2018). The cases in the iPSYCH2012 sample there-
fore represent the severe endof thedepressiondistribution in
Denmark, which is both a strength and a limitation. Severe
cases are likely enriched for genetic determinants16; how-
ever, the resultsmaynot generalize tomilder formsof depres-
sion, and they couldbebiased toward thenull becauseofmis-
classification.Additionally, theremaybe too little variation in
severity to assess the associations betweenpolygenic liability
and severity in this sample. The analysesmay also be subject
to selectionbias if peoplewith specialty-treateddepressionare
more likely thanpeoplewithuntreatedorprimary-care treated
depression to experience recurrent episodes.
Becausewe focusedexclusivelyon firstdepression,wedid
notaccount for subsequentdiagnostic conversions toBDorSZ.
Individuals who convert may have different genetic profiles;
however, therewas noway to account for thiswithout condi-
tioning on the future, which can introduce bias.48 Further re-
search is needed to investigate the associationsbetweenpoly-
genic liability and the characteristics of course and outcome,
including progression to other psychiatric disorders. Finally,
thediscoverydata sets used to create thepolygenic risk scores
for MD, BD, and SZ had different sample sizes, which affects
their statistical power.49
Conclusions
We found that polygenic liability is associated with depres-
sion in the general Danishpopulation. Polygenic liabilities for
BD and SZ were also associated with depression, which sup-
ports the idea that there is a shared genetic predisposition
across these disorders. Heterogeneity in AAO might be par-
tially attributable to underlying genetic differences among
depression cases, but these associations appear minimal.
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